Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Author’ response
Author’s reply
Authors' response
Authors#x2019; response
Book Received
Book Review
Book Reviews
Centenary Review Article
Clinical Image
Clinical Images
Commentary
Communicable Diseases - Original Articles
Correspondence
Correspondence, Letter to Editor
Correspondences
Correspondences & Authors’ Responses
Corrigendum
Critique
Current Issue
Editorial
Errata
Erratum
Health Technology Innovation
IAA CONSENSUS DOCUMENT
Innovations
Letter to Editor
Malnutrition & Other Health Issues - Original Articles
Media & News
Notice of Retraction
Obituary
Original Article
Original Articles
Perspective
Perspectives
Policy
Policy Document
Policy Guidelines
Policy, Review Article
Policy: Correspondence
Policy: Editorial
Policy: Mapping Review
Policy: Original Article
Policy: Perspective
Policy: Process Paper
Policy: Scoping Review
Policy: Special Report
Policy: Systematic Review
Policy: Viewpoint
Practice
Practice: Authors’ response
Practice: Book Review
Practice: Clinical Image
Practice: Commentary
Practice: Correspondence
Practice: Letter to Editor
Practice: Obituary
Practice: Original Article
Practice: Pages From History of Medicine
Practice: Perspective
Practice: Review Article
Practice: Short Note
Practice: Short Paper
Practice: Special Report
Practice: Student IJMR
Practice: Systematic Review
Pratice, Original Article
Pratice, Review Article
Pratice, Short Paper
Programme
Programme, Correspondence, Letter to Editor
Programme: Commentary
Programme: Correspondence
Programme: Editorial
Programme: Original Article
Programme: Originial Article
Programme: Perspective
Programme: Rapid Review
Programme: Review Article
Programme: Short Paper
Programme: Special Report
Programme: Status Paper
Programme: Systematic Review
Programme: Viewpoint
Protocol
Research Correspondence
Retraction
Review Article
Short Paper
Special Opinion Paper
Special Report
Special Section Nutrition & Food Security
Status Paper
Status Report
Strategy
Student IJMR
Systematic Article
Systematic Review
Systematic Review & Meta-Analysis
Viewpoint
White Paper
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Author’ response
Author’s reply
Authors' response
Authors#x2019; response
Book Received
Book Review
Book Reviews
Centenary Review Article
Clinical Image
Clinical Images
Commentary
Communicable Diseases - Original Articles
Correspondence
Correspondence, Letter to Editor
Correspondences
Correspondences & Authors’ Responses
Corrigendum
Critique
Current Issue
Editorial
Errata
Erratum
Health Technology Innovation
IAA CONSENSUS DOCUMENT
Innovations
Letter to Editor
Malnutrition & Other Health Issues - Original Articles
Media & News
Notice of Retraction
Obituary
Original Article
Original Articles
Perspective
Perspectives
Policy
Policy Document
Policy Guidelines
Policy, Review Article
Policy: Correspondence
Policy: Editorial
Policy: Mapping Review
Policy: Original Article
Policy: Perspective
Policy: Process Paper
Policy: Scoping Review
Policy: Special Report
Policy: Systematic Review
Policy: Viewpoint
Practice
Practice: Authors’ response
Practice: Book Review
Practice: Clinical Image
Practice: Commentary
Practice: Correspondence
Practice: Letter to Editor
Practice: Obituary
Practice: Original Article
Practice: Pages From History of Medicine
Practice: Perspective
Practice: Review Article
Practice: Short Note
Practice: Short Paper
Practice: Special Report
Practice: Student IJMR
Practice: Systematic Review
Pratice, Original Article
Pratice, Review Article
Pratice, Short Paper
Programme
Programme, Correspondence, Letter to Editor
Programme: Commentary
Programme: Correspondence
Programme: Editorial
Programme: Original Article
Programme: Originial Article
Programme: Perspective
Programme: Rapid Review
Programme: Review Article
Programme: Short Paper
Programme: Special Report
Programme: Status Paper
Programme: Systematic Review
Programme: Viewpoint
Protocol
Research Correspondence
Retraction
Review Article
Short Paper
Special Opinion Paper
Special Report
Special Section Nutrition & Food Security
Status Paper
Status Report
Strategy
Student IJMR
Systematic Article
Systematic Review
Systematic Review & Meta-Analysis
Viewpoint
White Paper
View/Download PDF

Translate this page into:

Original Article
133 (
3
); 308-311
pmid:
21441685

Prevalence of multidrug-resistant tuberculosis among newly diagnosed cases of sputum-positive pulmonary tuberculosis

Department of Medicine, All India Institute of Medical Sciences, New Delhi, India
Department of Microbiology, All India Institute of Medical Sciences, New Delhi, India
Department of Microbiology, Sanjay Gandhi Memorial Hospital, New Delhi, India
New Delhi Tuberculosis Centre, New Delhi, India

Reprint requests: Prof. S.K. Sharma, Chief, Division of Pulmonary, Critical Care & Sleep Medicine, Head, Department of Medicine, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110 029, India e-mail: sksharma@aiims.ac.in, sksharma.aiims@gmail.com

Licence

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Disclaimer:
This article was originally published by Medknow Publications and was migrated to Scientific Scholar after the change of Publisher.

Abstract

Background & objectives:

The prevalence of multidrug-resistant tuberculosis (MDR-TB) is increasing throughout the world. Although previous treatment for TB is the most important risk factor for development of MDR-TB, treatment-naïve patients are also at risk due to either spontaneous mutations or transmission of drug-resistant strains. We sought to ascertain the prevalence of MDR-TB among new cases of sputum-positive pulmonary TB.

Methods:

This was a prospective, observational study involving newly diagnosed cases of sputum-positive pulmonary tuberculosis diagnosed between 2008 and 2009 carried out in New Delhi, India. All sputum-positive TB cases were subjected to mycobacterial culture and first-line drug-susceptibility testing (DST). MDR-TB was defined as TB caused by bacilli showing resistance to at least isoniazid and rifampicin.

Results:

A total of 218 cases of sputum-positive pulmonary tuberculosis were enrolled between 2008 and 2009. Of these, 41 cases had negative mycobacterial cultures and DST was carried out in 177 cases. The mean age of the patients was 27.8 ± 10.2 yr; 59 patients (27%) were female. All patients tested negative for HIV infection. Out of 177 cases, two cases of MDR-TB were detected. Thus, the prevalence of MDR-TB among newly diagnosed pulmonary tuberculosis patients was 1.1 per cent.

Interpretation & conclusions:

MDR-TB prevalence is low among new cases of sputum-positive pulmonary TB treated at primary care level in Delhi. Nation-wide and State-wide representative data on prevalence of MDR-TB are lacking. Efforts should be directed towards continued surveillance for MDR-TB among newly diagnosed TB cases.

Keywords

Drug resistance
India
multidrug-resistant tuberculosis (MDR-TB)
new case-pulmonary tuberculosis

The emergence and spread of multi-drug resistant tuberculosis (MDR-TB) is threatening to destabilize global tuberculosis control. The prevalence of MDR-TB is increasing throughout the world both among new tuberculosis cases as well as among previously-treated ones1. Although previous treatment for TB is the strongest risk factor for development of MDR-TB24, treatment-naïve patients are also at risk due to either spontaneous mutations or transmission of resistant strains56. The risk of transmission of resistant strains from close contacts is increasing day-by-day because of the growing burden of MDR-TB patients1. Therefore, in the present scenario, there is high likelihood that what initially seems to be drug-sensitive TB in a treatment-naïve patient might in fact be MDR-TB from the outset. Therefore, we sought to determine the prevalence of MDR-TB among new cases of sputum-positive pulmonary TB.

Material & Methods

This was a prospective, observational study involving newly diagnosed cases of sputum-positive pulmonary tuberculosis. These are preliminary results from an ongoing double-blind, placebo-controlled trial. The cases were recruited through a dedicated chest clinic functioning at primary care level at Sanjay Gandhi Memorial Hospital in Mongolpuri, New Delhi. All suspected cases of TB attending the clinic were subjected to sputum smear examination and mycobacterial culture and drug-susceptibility testing (DST) at the New Delhi Tuberculosis (NDTB) Centre laboratory, New Delhi. The NDTB centre was accredited as the intermediate reference laboratory (IRL) during the study period. Sputum-positive pulmonary TB was defined as TB in a patient with at least 2 initial sputum smear examinations positive for acid-fast bacilli (AFB) or one sputum smear examination positive for AFB and radiographic abnormalities consistent with active pulmonary TB or one sputum smear specimen positive for AFB and culture positive for Mycobacterium tuberculosis7. New case was defined as a TB patient who has never had treatment for tuberculosis or has taken anti-tuberculosis drugs for less than one month7. Cultures were done on Lowenstein-Jensen (L-J) slopes by modified Petroff’s method8. All the isolates were identified as M. tuberculosis by their slow growth rate, colony morphology, inability to grow on L-J media containing p-nitrobenzoic acid (PNB), niacin test and catalase test. DST was carried out by the economic variant of 1 per cent proportion method for all drugs except pyrazinamide which was tested by the resistance-ratio method. The tested drugs and their critical concentrations (in μg/ml) were as follows: isoniazid (H)- 0.2, rifampicin (R)- 40, pyrazinamide (Z) - 100, ethambutol (E) - 2 and streptomycin (S) - 4. MDR-TB was defined as TB caused by bacilli showing resistance to at least isoniazid and rifampicin. Human immunodeficiency virus (HIV) testing was carried out routinely in all patients and HIV positive patients were excluded from the study. Written informed consent was obtained from all patients. The Ethical Committee of AIIMS hospital, New delhi approved the study protocol.

Results

We prospectively enrolled 218 cases of newly diagnosed sputum-positive pulmonary tuberculosis between February 2008 and December 2009. Of the 218 cases, 41 patients had negative mycobacterial cultures and hence DST was carried out in 177 cases. The mean age of the patients was 27.8 ± 10.2 yr; 59 (27%) were female. The mean body mass index (BMI) was 17.33 ± 1.99 kg/m2. Out of 177 cases, two cases of MDR-TB were detected. Both were male, HIV negative, aged 20 and 25 yr with BMI 17.1 and 19.7 kg/m 2, and resistance pattern was H, R, S and H, R, E, S, respectively. Thus, the prevalence of MDR-TB among new sputum positive pulmonary TB patients was 1.1 per cent. The resistance rates (%) observed to various first-line drugs were isoniazid 6.2, rifampicin 1.1, pyrazinamide 0, ethambutol 3.4, and streptomycin 2.3. The rates of mono- and poly-drug resistance rates are shown in Table I.

Table I Mono- and poly-drug resistance rates in patients
Drug Resistance rate (%)
Isoniazid 1.7
Rifampicin 0
Pyrazinamide 0
Ethambutol 0
Streptomycin 0
Isoniazid + Ethambutol 2.3
Isoniazid + Streptomycin 0.6
Isoniazid + Rifampicin + Streptomycin 0.6
Isoniazid + Ethambutol + Streptomycin 0.6
Isoniazid + Rifampicin Ethambutol + Streptomycin 0.6

Note:The drug combinations not mentioned in this Table had 0%resistance.

Discussion

We found a low prevalence of MDR-TB among new cases of pulmonary TB in Delhi. The reported prevalence of MDR-TB among new TB cases has varied from 0.14 to 5.3 per cent in previous studies from different parts of India819 and our findings are in consonance with such observations (Table II). But there are a few studies which have reported a high prevalence of MDR-TB among new TB cases2021. Bias in patient selection and differences in methodology may account for such high prevalence of MDR-TB noted in these studies.

Our findings carry some important implications. Firstly, the prevalence of MDR-TB has not risen over the years, which reflects the success of DOTS in effective treatment of drug-susceptible TB and preventing the emergence of MDR-TB. Secondly, since MDR-TB is rare among new TB cases, all new cases of pulmonary tuberculosis can be treated with empirical category I regimen without the risk of treatment failures or aggravation of drug-resistance.

The major limitation of the present study is the small sample size and therefore, it is not representative of the population at large. In fact, this limitation was observed in most previous studies on MDR-TB. Nation-wide and State-wide representative data on the prevalence of MDR-TB are an urgent need of the hour to design effective empirical regimens, to monitor functioning and progress of the national TB control programme and for continued surveillance of MDR-TB among category I TB patients. In conclusion, our findings are quite reassuring in that MDR-TB prevalence has not risen over the years and still continues to be low among new cases of pulmonary TB.

Table II Prevalence of MDR-TB among new cases of pulmonary TB in India reported in previous studies
Location Period of study No. of isolates MDR-TB (%)
Bangalore8 1980s 436 1.1
Wardha9 1982-1989 323 5.3
North Arcot10 1985-1989 2779 1.6
Pondicherry10 1985-1991 1841 0.8
Kolar11 1987-1989 292 3.4
Jaipur12 1989-1991 1009 0.9
New Delhi13 1990-1991 324 0.6
Pune14 1992-1993 473 1.0
Tamil Nadu15 1997 384 3.4
North Arcot16 1999 282 2.8
Lucknow20 2000-2002 318 13.2
Hyderabad17 2001-2003 714 0.14
Ernakulam18 2004 305 2.0
Gujarat19 - 1571 2.4
Mumbai21 2004-2007 493 24
Present study 2008-2009 177 1.1

Authors thank the Department of Biotechnology, Ministry of Science and Technology, Govt. of India (BT/PR7894/Med/14/1175/2006) for financial assistance.

Conflicts of Interest: We declare that we have no conflict of interest.

References

  1. The WHO / IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance. In: Anti-Tuberculosis Drug Resistance in the World. Report No.4. Geneva, Switzerland: WHO; . p. :394. WHO/HTM/TB/2008
    [Google Scholar]
  2. , , . Multidrug-resistant tuberculosis: a menace that threatens to destabilize tuberculosis control. Chest. 2006;130:261-72.
    [Google Scholar]
  3. , , , , , , . Determinants of drug-resistant tuberculosis: analysis of 11 countries. Int J Tuberc Lung Dis. 2001;5:887-93.
    [Google Scholar]
  4. , , , , , , . A case-control study for multidrug-resistant tuberculosis: risk factors in four European countries. Microb Drug Resist. 2005;11:62-7.
    [Google Scholar]
  5. , , . Drug resistance in tuberculosis in India. Indian J Med Res. 2004;120:377-86.
    [Google Scholar]
  6. , , , , , . Infection and disease among contacts of tuberculosis cases with drug resistant and drug susceptible bacilli. Am Rev Respir Dis. 1985;132:125-32.
    [Google Scholar]
  7. Revised National Tuberculosis Control Programme (RNTCP). RNTCP at a glance. Central TB Division, Directorate General of Health Services, Ministry of Health and Family Welfare, New Delhi, Government of India. Available from: http:// uttarkashi.nic.in/Dept/Health/ RNTCP/ RNTCP.pdf accessed on January 26, 2010
    [Google Scholar]
  8. , , , , , . Initial drug resistance to anti-tuberculosis drugs in patients attending an urban district tuberculosis centre. Indian J Tuberc. 1990;37:215-6.
    [Google Scholar]
  9. , , , , , . Smear and culture positive cases of pulmonary tuberculosis found among symptomatics surveyed in Wardha district. Indian J Tuberc. 1992;39:159-63.
    [Google Scholar]
  10. , , , , , . Bacteriological investigations for short course chemotherapy under the tuberculosis programme in two districts of India. Tuber Lung Dis. 1993;74:23-7.
    [Google Scholar]
  11. , , , . Initial drug resistance to antituberculosis drugs in urban and rural district tuberculosis programme. Indian J Tuberc. 1992;39:171-5.
    [Google Scholar]
  12. , , , , . Prevalence of initial drug resistance in tuberculosis patients attending a chest hospital. Indian J Med Res. 1993;97:102-3.
    [Google Scholar]
  13. , , , . Initial and acquired isoniazid and rifampicin resistance to Mycobacterium tuberculosis and its implication for treatment. Indian J Tuberc. 1992;39:12-4.
    [Google Scholar]
  14. , , , , , . Drug resistance pattern of Mycobacterium tuberculosis in a chest diseases hospital of armed forces. Lung India. 1995;13:56-9.
    [Google Scholar]
  15. , , , , , . Surveillance of drug resistance in tuberculosis in the state of Tamil Nadu. Indian J Tuberc. 2000;47:27-33.
    [Google Scholar]
  16. , , , , , . Surveillance of drug resistance in tuberculosis in two districts of south India. Int J Tuberc Lung Dis. 2002;6:479-84.
    [Google Scholar]
  17. , , , , , , . Prevalence of drug resistance under the DOTS strategy in Hyderabad, South India, 2001-2003. Int J Tuberc Lung Dis. 2006;10:58-62.
    [Google Scholar]
  18. , , , , , . Surveillance of anti-tuberculosis drug resistance in Ernakulam District, Kerala State, South India. Int J Tuberc Lung Dis. 2007;11:443-9.
    [Google Scholar]
  19. , , , , , , . Surveillance of drug-resistant tuberculosis in the state of Gujarat, India. Int J Tuberc Lung Dis. 2009;13:1154-60.
    [Google Scholar]
  20. , , , , , . Prevalence of multidrug resistant Mycobacterium tuberculosis in Lucknow, Uttar Pradesh. Indian J Med Res. 2008;128:300-6.
    [Google Scholar]
  21. , , , , , , . High levels of multidrug resistant tuberculosis in new and treatment-failure patients from the Revised National Tuberculosis Control Programme in an urban metropolis (Mumbai) in Western India. BMC Public Health. 2009;211:1-9.
    [Google Scholar]
Show Sections
Scroll to Top